Jüngste Fortschritte in der Therapie des Kolonkarzinoms View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2006-02

AUTHORS

Peter C. Thuss-Patience, Peter Reichardt, Hanno Riess, Albrecht Kretzschmar

ABSTRACT

BACKGROUND: Considerable progress has been made in the treatment of colorectal cancer. Many new results have been presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in May 2005 at Orlando, FL, USA. METHODS: This update describes the highlights of the ASCO 2005 conference and the most recent publications in this field. RESULTS AND CONCLUSION: Therapy of metastatic colorectal cancer: studies could demonstrate that capecitabine can possibly replace 5-fluorouracil (5-FU) in combination regimens with oxaliplatin. The EGF receptor antibody cetuximab shows activity as single agent and in combination with irinotecan. Combination with oxaliplatin/5-FU is under investigation. The VEGF antibody bevacizumab leads to improved efficacy in combination with all chemotherapies investigated so far, but shows no efficacy as single agent. Adjuvant therapy of colon cancer: oxaliplatin and 5-FU improves the disease-free survival compared with 5-FU regimens and is the new standard adjuvant treatment for stage III disease. Capecitabine demonstrates better tolerability and at least equal efficacy as 5-FU bolus regimens and should replace these regimens whenever an oxaliplatin-based therapy is not chosen. Irinotecan does not improve disease-free survival and has no proven benefit in the adjuvant setting. Monoclonal antibodies are integrated in new adjuvant trials. More... »

PAGES

114-119

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00063-006-1016-x

DOI

http://dx.doi.org/10.1007/s00063-006-1016-x

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1001102032

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/16501908


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Clinical Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Colorectal Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Staging", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Rate", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Freie Universit\u00e4t Berlin", 
          "id": "https://www.grid.ac/institutes/grid.14095.39", 
          "name": [
            "Charit\u00e9 Universit\u00e4tsmedizin Berlin, Campus Virchow-Klinikum, Medizinische Klinik mit Schwerpunkt H\u00e4matologie und Onkologie, Berlin", 
            "Charit\u00e9, Universit\u00e4tsmedizin Berlin, Campus Virchow-Klinikum, Medizinische Klinik mit Schwerpunkt H\u00e4matologie und Onkologie (Direktor: Prof. Dr. med. B. D\u00f6rken), Augustenburger Platz 1, 13353, Berlin"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Thuss-Patience", 
        "givenName": "Peter C.", 
        "id": "sg:person.01264411101.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01264411101.13"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Virchow Klinikum", 
          "id": "https://www.grid.ac/institutes/grid.418434.e", 
          "name": [
            "Charit\u00e9 Universit\u00e4tsmedizin Berlin, Campus Virchow-Klinikum, Medizinische Klinik mit Schwerpunkt H\u00e4matologie und Onkologie, Berlin"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Reichardt", 
        "givenName": "Peter", 
        "id": "sg:person.01111517020.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01111517020.19"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Virchow Klinikum", 
          "id": "https://www.grid.ac/institutes/grid.418434.e", 
          "name": [
            "Charit\u00e9 Universit\u00e4tsmedizin Berlin, Campus Virchow-Klinikum, Medizinische Klinik mit Schwerpunkt H\u00e4matologie und Onkologie, Berlin"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Riess", 
        "givenName": "Hanno", 
        "id": "sg:person.01326400451.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01326400451.24"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Helios Hospital Berlin-Buch", 
          "id": "https://www.grid.ac/institutes/grid.491869.b", 
          "name": [
            "Charit\u00e9 Campus Buch, Robert-R\u00f6ssle-Klinik, HELIOS-Klinikum Berlin-Buch, Berlin"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kretzschmar", 
        "givenName": "Albrecht", 
        "id": "sg:person.01003225440.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01003225440.16"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2006-02", 
    "datePublishedReg": "2006-02-01", 
    "description": "BACKGROUND: Considerable progress has been made in the treatment of colorectal cancer. Many new results have been presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in May 2005 at Orlando, FL, USA.\nMETHODS: This update describes the highlights of the ASCO 2005 conference and the most recent publications in this field.\nRESULTS AND CONCLUSION: Therapy of metastatic colorectal cancer: studies could demonstrate that capecitabine can possibly replace 5-fluorouracil (5-FU) in combination regimens with oxaliplatin. The EGF receptor antibody cetuximab shows activity as single agent and in combination with irinotecan. Combination with oxaliplatin/5-FU is under investigation. The VEGF antibody bevacizumab leads to improved efficacy in combination with all chemotherapies investigated so far, but shows no efficacy as single agent. Adjuvant therapy of colon cancer: oxaliplatin and 5-FU improves the disease-free survival compared with 5-FU regimens and is the new standard adjuvant treatment for stage III disease. Capecitabine demonstrates better tolerability and at least equal efficacy as 5-FU bolus regimens and should replace these regimens whenever an oxaliplatin-based therapy is not chosen. Irinotecan does not improve disease-free survival and has no proven benefit in the adjuvant setting. Monoclonal antibodies are integrated in new adjuvant trials.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00063-006-1016-x", 
    "inLanguage": [
      "de"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1017977", 
        "issn": [
          "0723-5003", 
          "1615-6722"
        ], 
        "name": "Medizinische Klinik", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "101"
      }
    ], 
    "name": "J\u00fcngste Fortschritte in der Therapie des Kolonkarzinoms", 
    "pagination": "114-119", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "05402131fa6b2f1535fa75a5d820f41ba65a17dd40d66b0e2988c2a5d56cb561"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "16501908"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8303501"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00063-006-1016-x"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1001102032"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00063-006-1016-x", 
      "https://app.dimensions.ai/details/publication/pub.1001102032"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T21:34", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8687_00000502.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs00063-006-1016-x"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00063-006-1016-x'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00063-006-1016-x'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00063-006-1016-x'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00063-006-1016-x'


 

This table displays all metadata directly associated to this object as RDF triples.

121 TRIPLES      20 PREDICATES      35 URIs      27 LITERALS      15 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00063-006-1016-x schema:about N303dc1e4aaa3410c806a776656e93540
2 N37ded19d5854471cb08771a7973d7266
3 N4686287de5794a50a55b4aa861933d06
4 N67dac858ca8d43a2933701e5459b2d0f
5 N874d20868bd54c96bcd66afc22212d45
6 Naf484f86a8924634a4a3d6b438c02ba1
7 anzsrc-for:11
8 anzsrc-for:1112
9 schema:author Nd9bf6c150ed045459bafdcc4f59cc3a5
10 schema:datePublished 2006-02
11 schema:datePublishedReg 2006-02-01
12 schema:description BACKGROUND: Considerable progress has been made in the treatment of colorectal cancer. Many new results have been presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in May 2005 at Orlando, FL, USA. METHODS: This update describes the highlights of the ASCO 2005 conference and the most recent publications in this field. RESULTS AND CONCLUSION: Therapy of metastatic colorectal cancer: studies could demonstrate that capecitabine can possibly replace 5-fluorouracil (5-FU) in combination regimens with oxaliplatin. The EGF receptor antibody cetuximab shows activity as single agent and in combination with irinotecan. Combination with oxaliplatin/5-FU is under investigation. The VEGF antibody bevacizumab leads to improved efficacy in combination with all chemotherapies investigated so far, but shows no efficacy as single agent. Adjuvant therapy of colon cancer: oxaliplatin and 5-FU improves the disease-free survival compared with 5-FU regimens and is the new standard adjuvant treatment for stage III disease. Capecitabine demonstrates better tolerability and at least equal efficacy as 5-FU bolus regimens and should replace these regimens whenever an oxaliplatin-based therapy is not chosen. Irinotecan does not improve disease-free survival and has no proven benefit in the adjuvant setting. Monoclonal antibodies are integrated in new adjuvant trials.
13 schema:genre research_article
14 schema:inLanguage de
15 schema:isAccessibleForFree false
16 schema:isPartOf N60d158b03b75461aac408f4d02630c10
17 Nfd42e870b7a94222bd332d6cf0a07764
18 sg:journal.1017977
19 schema:name Jüngste Fortschritte in der Therapie des Kolonkarzinoms
20 schema:pagination 114-119
21 schema:productId N0d3c96026dba453a9d054c54c3b6482b
22 N2628122d14ae47dbb3ce3190800d8317
23 N3857005fec1243f095b57e9b062d1677
24 N8bc730d024584bad982a287be36339b4
25 Nef3b67d466d049f9953a2bba69ea2e73
26 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001102032
27 https://doi.org/10.1007/s00063-006-1016-x
28 schema:sdDatePublished 2019-04-10T21:34
29 schema:sdLicense https://scigraph.springernature.com/explorer/license/
30 schema:sdPublisher N6a43f414c4de433e9bedcbae7bd18f84
31 schema:url http://link.springer.com/10.1007%2Fs00063-006-1016-x
32 sgo:license sg:explorer/license/
33 sgo:sdDataset articles
34 rdf:type schema:ScholarlyArticle
35 N0238db53b26a4cfc841d8760f2361680 rdf:first sg:person.01111517020.19
36 rdf:rest Ne058b328925248a785c9f00a39fe715e
37 N0d3c96026dba453a9d054c54c3b6482b schema:name dimensions_id
38 schema:value pub.1001102032
39 rdf:type schema:PropertyValue
40 N2628122d14ae47dbb3ce3190800d8317 schema:name doi
41 schema:value 10.1007/s00063-006-1016-x
42 rdf:type schema:PropertyValue
43 N303dc1e4aaa3410c806a776656e93540 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
44 schema:name Humans
45 rdf:type schema:DefinedTerm
46 N37ded19d5854471cb08771a7973d7266 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
47 schema:name Neoplasm Staging
48 rdf:type schema:DefinedTerm
49 N3857005fec1243f095b57e9b062d1677 schema:name readcube_id
50 schema:value 05402131fa6b2f1535fa75a5d820f41ba65a17dd40d66b0e2988c2a5d56cb561
51 rdf:type schema:PropertyValue
52 N4686287de5794a50a55b4aa861933d06 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
53 schema:name Antineoplastic Combined Chemotherapy Protocols
54 rdf:type schema:DefinedTerm
55 N60d158b03b75461aac408f4d02630c10 schema:volumeNumber 101
56 rdf:type schema:PublicationVolume
57 N67dac858ca8d43a2933701e5459b2d0f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
58 schema:name Clinical Trials as Topic
59 rdf:type schema:DefinedTerm
60 N6a43f414c4de433e9bedcbae7bd18f84 schema:name Springer Nature - SN SciGraph project
61 rdf:type schema:Organization
62 N874d20868bd54c96bcd66afc22212d45 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
63 schema:name Colorectal Neoplasms
64 rdf:type schema:DefinedTerm
65 N8bc730d024584bad982a287be36339b4 schema:name nlm_unique_id
66 schema:value 8303501
67 rdf:type schema:PropertyValue
68 Naf484f86a8924634a4a3d6b438c02ba1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
69 schema:name Survival Rate
70 rdf:type schema:DefinedTerm
71 Nd9bf6c150ed045459bafdcc4f59cc3a5 rdf:first sg:person.01264411101.13
72 rdf:rest N0238db53b26a4cfc841d8760f2361680
73 Ne058b328925248a785c9f00a39fe715e rdf:first sg:person.01326400451.24
74 rdf:rest Neba1b6f11e4049928046fc449eecf448
75 Neba1b6f11e4049928046fc449eecf448 rdf:first sg:person.01003225440.16
76 rdf:rest rdf:nil
77 Nef3b67d466d049f9953a2bba69ea2e73 schema:name pubmed_id
78 schema:value 16501908
79 rdf:type schema:PropertyValue
80 Nfd42e870b7a94222bd332d6cf0a07764 schema:issueNumber 2
81 rdf:type schema:PublicationIssue
82 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
83 schema:name Medical and Health Sciences
84 rdf:type schema:DefinedTerm
85 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
86 schema:name Oncology and Carcinogenesis
87 rdf:type schema:DefinedTerm
88 sg:journal.1017977 schema:issn 0723-5003
89 1615-6722
90 schema:name Medizinische Klinik
91 rdf:type schema:Periodical
92 sg:person.01003225440.16 schema:affiliation https://www.grid.ac/institutes/grid.491869.b
93 schema:familyName Kretzschmar
94 schema:givenName Albrecht
95 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01003225440.16
96 rdf:type schema:Person
97 sg:person.01111517020.19 schema:affiliation https://www.grid.ac/institutes/grid.418434.e
98 schema:familyName Reichardt
99 schema:givenName Peter
100 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01111517020.19
101 rdf:type schema:Person
102 sg:person.01264411101.13 schema:affiliation https://www.grid.ac/institutes/grid.14095.39
103 schema:familyName Thuss-Patience
104 schema:givenName Peter C.
105 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01264411101.13
106 rdf:type schema:Person
107 sg:person.01326400451.24 schema:affiliation https://www.grid.ac/institutes/grid.418434.e
108 schema:familyName Riess
109 schema:givenName Hanno
110 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01326400451.24
111 rdf:type schema:Person
112 https://www.grid.ac/institutes/grid.14095.39 schema:alternateName Freie Universität Berlin
113 schema:name Charité Universitätsmedizin Berlin, Campus Virchow-Klinikum, Medizinische Klinik mit Schwerpunkt Hämatologie und Onkologie, Berlin
114 Charité, Universitätsmedizin Berlin, Campus Virchow-Klinikum, Medizinische Klinik mit Schwerpunkt Hämatologie und Onkologie (Direktor: Prof. Dr. med. B. Dörken), Augustenburger Platz 1, 13353, Berlin
115 rdf:type schema:Organization
116 https://www.grid.ac/institutes/grid.418434.e schema:alternateName Virchow Klinikum
117 schema:name Charité Universitätsmedizin Berlin, Campus Virchow-Klinikum, Medizinische Klinik mit Schwerpunkt Hämatologie und Onkologie, Berlin
118 rdf:type schema:Organization
119 https://www.grid.ac/institutes/grid.491869.b schema:alternateName Helios Hospital Berlin-Buch
120 schema:name Charité Campus Buch, Robert-Rössle-Klinik, HELIOS-Klinikum Berlin-Buch, Berlin
121 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...